Ahmedabad, Gujarat, India, April 2025 – Dr. Manish Kumar has taken on the role of Vice President – Research & Development, Biopharma at Intas Pharmaceuticals, returning to the organization to lead its advanced biosimilar R&D initiatives. With a career that spans over a decade and a half in CMC development, biocharacterization, and scientific strategy, Dr. Manish brings deep expertise and leadership experience in biologics and biosimilars.
In his new position, Dr. Manish will oversee end-to-end biopharma R&D operations with a strong focus on analytical sciences, functional characterization, and regulatory development. His mission will align with Intas’ larger goal of delivering “Biosimilars for Billions”, ensuring accessibility, quality, and global regulatory compliance across therapeutic segments.
Before rejoining Intas, Dr. Manish Kumar served as Head – ADCs, Process and Analytical Development at Dr. Reddy’s Laboratories, where he led the development and CMC strategy for novel Antibody-Drug Conjugates and advanced biopharma molecules. His leadership was instrumental in progressing clinical-stage programs and mentoring scientific talent.
Prior to this, Dr. Manish spent over seven years at Intas Pharmaceuticals in leadership roles, including Associate Vice President and Senior General Manager. He was responsible for integrated analytical functions across ADL, BDL, and CMC teams, playing a pivotal role in biosimilar development, bio-analytical methods, and functional characterization across various product lines.
He previously spent over seven years at Dr. Reddy’s Laboratories in roles including Principal Scientist, where he led a functional characterization team and CMC strategy for biosimilar candidates, driving them from early-stage development to clinical readiness.
Dr. Manish began his research career as a Postdoctoral Fellow at the University of Virginia Health System, where he spent nearly three years contributing to advanced biomedical research in a highly interdisciplinary environment.
About Intas Pharmaceuticals
Intas Pharmaceuticals is one of the world’s fastest-growing pharmaceutical formulation development and manufacturing organizations, with a presence in 85+ countries. Over 70% of its revenue comes from global markets. Through its Accord Healthcare subsidiaries and leadership in key therapeutic areas including CNS, Oncology, and Auto-immune diseases, Intas is a top 10 generic player in regulated markets like the US, EU, and UK.
Intas’ Biopharma division, with advanced EU-GMP certified facilities, focuses on delivering affordable biosimilars across oncology, rheumatology, nephrology, and more. Backed by 23,000+ professionals, Intas continues to drive innovation with a 6–7% annual R&D investment, building a strategic pipeline of 300+ products.
Read Also : Entering 2025, TA Leaders’ Success Built on More than Just Hiring, Says The Josh Bersin Company
People Analytics Teams Still Struggle to Deliver Business Impact, Warns The Josh Bersin Company
ESG and Women’s Leadership: Driving Sustainability and Inclusion
Learning and Development Trends for 2025: Shaping the Future of Workplace Learning
